A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a Pediatric Brain Tumor Consortium report†

A phase II study of the PARP inhibitor ABT-888 plus temozolomide in patients with heavily pretreated, metastatic colorectal cancer.

(2017) M. J. Pishvaian et al.   JOURNAL OF CLINICAL ONCOLOGY

PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation

(2015) Dannis Gilbert Van Vuurden et al.   Oncotarget

A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas

(2012) S. Kummar et al.   CLINICAL CANCER RESEARCH

Synthetic Lethal Interactions between EGFR and PARP Inhibition in Human Triple Negative Breast Cancer Cells

(2012) Somaira Nowsheen et al.   PLoS One

Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors

(2011) P. Neri et al.   BLOOD

Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas

(2011) S. Kummar et al.   CANCER RESEARCH

Phase I Trial of MK-0752 in Children With Refractory CNS Malignancies: A Pediatric Brain Tumor Consortium Study

(2011) Maryam Fouladi et al.   JOURNAL OF CLINICAL ONCOLOGY

Response of Human Prostate Cancer Cells and Tumors to Combining PARP Inhibition with Ionizing Radiation

(2011) J. C. Barreto-Andrade et al.   MOLECULAR CANCER THERAPEUTICS

Pediatric high-grade glioma: identification of poly(ADP-ribose) polymerase as a potential therapeutic target

(2011) S. J. Smith et al.   NEURO-ONCOLOGY

Modeling Pharmacodynamic Response to the Poly(ADP-Ribose) Polymerase Inhibitor ABT-888 in Human Peripheral Blood Mononuclear Cells

(2011) Jiuping Ji et al.   PLoS One

The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy

(2011) Somaira Nowsheen et al.   RADIOTHERAPY AND ONCOLOGY

PTEN Loss Compromises Homologous Recombination Repair in Astrocytes: Implications for Glioblastoma Therapy with Temozolomide or Poly(ADP-Ribose) Polymerase Inhibitors

(2010) B. McEllin et al.   CANCER RESEARCH

Gene Expression Profile ofBRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer

(2010) Panagiotis A. Konstantinopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

Whole-Genome Profiling of Pediatric Diffuse Intrinsic Pontine Gliomas Highlights Platelet-Derived Growth Factor Receptor α and Poly (ADP-ribose) Polymerase As Potential Therapeutic Targets

(2010) Maryam Zarghooni et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

(2010) M William Audeh et al.   LANCET

Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates

(2009) Jodi A. Muscal et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors

(2009) J. P. Palma et al.   CLINICAL CANCER RESEARCH

Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies

(2009) Shivaani Kummar et al.   JOURNAL OF CLINICAL ONCOLOGY

PARP1 expression in pediatric central nervous system tumors

(2009) Valerie N. Barton et al.   PEDIATRIC BLOOD & CANCER

An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors

(2008) Xuesong Liu et al.   ANALYTICAL BIOCHEMISTRY

A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia

(2008) Stanley K. Liu et al.   RADIOTHERAPY AND ONCOLOGY